Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers
Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers
复制标题
DOI：
10.5306/wjco.v2.i3.158
复制
发表时间：
2011-03-10
影响因子：
2.8
通讯作者：
Koike, Kazuhiko
中科院分区：
文献类型：
--
作者：
Tada, Minoru;Nakai, Yousuke;Koike, Kazuhiko
十多年来，吉西他滨化疗一直是晚期胰腺癌的标准治疗。新的口服氟嘧啶如S-1和卡培他滨是其他关键药物。吉西他滨加厄洛替尼是唯一能显著延长生存期的联合治疗，尽管效果很小。最近的分子靶向药物对生存率的改善很少或没有，这可能是由于胰腺癌中K-ras基因突变的发生率很高。最近，FOL-FIRINOX非吉西他滨基础方案首次显示总生存期显著高于吉西他滨。对于胆道癌，吉西他滨加顺铂联合化疗已被证明可显著延长生存期，并将成为标准治疗方案。通过添加西妥昔单抗，预期生存率会进一步改善。(C)2011年百世登。All rights reserved.
Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade. New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs. Gemcitabine plus erlotinib was the only combination therapy that significantly prolonged survival, although the effect was minimal. Little or no improvement in survival with recent molecular-targeted drugs might be attributed to the very high incidence of K-ras gene mutation in pancreatic cancer. Recently, the non-gemcitabine-based-regimen of FOL-FIRINOX showed significantly greater overall survival compared with gemcitabine for the first time. For biliary tract cancer, gemcitabine plus cisplatin combination chemotherapy has been proved to significantly prolong survival and will become the standard therapy. Further improvement in survival is expected by the addition of cetuximab. (C) 2011 Baishideng. All rights reserved.